SC grills Sebi over lingering probe against Sandesara brothers despite Rs 5,100 cr settlement

In a surprising turn of events, the Supreme Court has scrutinised Sebi's ongoing actions against the directors of Sterling Biotech. This review arises following the directors’ hefty ₹5,100 crore settlement payment. Earlier, the court had invalidated all related cases. Sebi's investigation concerns the suspected routing of funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cGoaAPK
via IFTTT